Visão geral da empresa
A clinical stage biotechnology firm, Entera Bio Ltd. focuses on the development of oral peptides and protein replacement therapies, with a specific emphasis on oral teriparatide known as EB613 for the treatment of osteoporosis in Israel and international markets. The company operates within the broader Healthcare sector, specifically classified under the Biotechnology industry, which characterizes entities engaged in the discovery and development of new pharmaceutical products rather than the commercialization of established drugs. Currently, the organization employs a small workforce of 20 individuals, indicating a lean operational structure typical of early-stage development firms. With a market capitalization of $62.62M and annual revenue reported at $42,000, the valuation metrics suggest that the market values Entera Bio significantly higher than its current revenue generation, reflecting high expectations for future clinical successes rather than current profitability. The discrepancy between the substantial market cap and negligible revenue highlights that the company's position is driven entirely by the potential value of its pipeline assets and intellectual property rather than existing cash flows or sales performance.
Saúde financeira
The financial statements for the trailing twelve months reveal a revenue of $42,000 against a net income loss of $11,439,000, while EBITDA stands at -$11,499,000. The significant gap between the minimal revenue figure and the substantial negative net income indicates an extreme cost structure where operating expenses, likely dominated by research and development costs for clinical trials, vastly outweigh any income generated from product sales. This financial reality is further underscored by a free cash flow of -$11,443,625, which demonstrates that the company is consuming cash reserves rapidly to fund its operations and development programs. The cash on hand totals $7.11M, providing a finite runway to support these cash-burning activities before additional capitalization is required. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of -27450.0%, and a profit margin of 0.0%, all pointing to a business model that has not yet achieved commercial scalability or profitability. Regarding leverage, the company holds $490,000 in debt against $7.11M in cash, resulting in a debt-to-equity ratio of 3.74, which suggests a leveraged balance sheet structure despite the low absolute debt amount. Liquidity is supported by a current ratio of 6.94, indicating that the company possesses ample short-term assets relative to its short-term obligations to cover immediate financial needs. Finally, the return on equity is -108.0% and the return on assets is -56.8%, metrics that reveal that management's efforts have not yet generated positive returns on the capital invested or the assets held, reflecting the inherent losses associated with the clinical development phase.
Avaliação de valorização
Valuation multiples for Entera Bio present a complex picture due to the lack of traditional profitability metrics. The trailing P/E ratio is listed as N/A because of the negative earnings, while the forward P/E is -2.09, a figure that implies the market is pricing in future earnings recovery or is utilizing a specific calculation methodology for loss-making biotech firms. The price-to-book ratio stands at 4.05, indicating that the market values the company at four times its book value, suggesting a premium assigned to the potential future value of its clinical pipeline rather than current tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 1490.89 and an EV/EBITDA of -4.09 further illustrate that standard valuation models are less applicable here, as the high P/S ratio reflects the market's willingness to pay a large multiple for a company with minimal sales. The stock has experienced significant price volatility within the last year, trading between a 52-week high of $3.22 and a 52-week low of $0.91. Without a specific current price provided in the data to calculate the exact percentage difference, the range itself demonstrates a wide trading band of approximately $2.31, or roughly 251%, between the yearly extremes. The beta value of 1.54 indicates that the stock's price volatility is 54% higher than the broader market, exposing investors to greater fluctuations in value compared to large-cap equities.
Growth & Income
Growth metrics for Entera Bio reflect the typical challenges faced by clinical stage companies in the biotechnology sector. Revenue growth year-over-year is recorded at -100.0%, and earnings growth is N/A due to the company's consistent losses, indicating that the business has not yet transitioned from R&D spending to revenue generation. Since the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it is clear that the organization reinvests all available resources and earnings—however small—back into its research and development efforts to advance its drug candidates. The absence of a dividend policy is consistent with a firm that prioritizes capital allocation toward clinical trials and regulatory approval processes over shareholder distributions. Consequently, the overall growth and income profile is characterized by negative revenue growth and a complete absence of income distribution, relying entirely on the successful progression of its drug candidates to future profitability.